Roles of GST-π and polβ Genes in Chemoresistance of Esophageal Carcinoma Cells

  • Tang, Yue (College of Basic Medical Sciences, Zhengzhou University) ;
  • Xuan, Xiao-Yan (College of Basic Medical Sciences, Zhengzhou University) ;
  • Li, Min (College of Basic Medical Sciences, Zhengzhou University) ;
  • Dong, Zi-Ming (College of Basic Medical Sciences, Zhengzhou University)
  • Published : 2013.12.31


The main aim of this study was to investigate the roles of GST-${\pi}$ and $pol{\beta}$ genes in the chemoresistance of esophageal carcinoma cells. Eukaryotic expression vectors containing each gene were constructed and transfected into EC9706 cells, and the biological effects of the two genes assessed based on a resistance index. We additionally investigated the in vitro and in vivo anti-resistance effects of GST-${\pi}$ and $pol{\beta}$ genes using recombinant lentiviruses carrying siRNAs against the two genes. Our results showed that upregulation of GST-${\pi}$ and $pol{\beta}$ genes suppresses chemosensitivity of esophageal carcinoma cells to cisplatin, while downregulation of these two genes with RNAi technology reverses this chemoresistance. Multi-site injection of recombinant lentivirus targeting the GST-${\pi}$ gene into transplanted cDDP tumors effectively reversed their chemoresistant phenotype. However, the same treatment against the $pol{\beta}$ gene did not lead to significant efficacy against chemoresistance.


  1. Al-Lazikani B, Banerji U, Workman P (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol, 30, 679-92.
  2. Bock C, Lengauer T (2012). Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer, 12, 494-501.
  3. Bouwman P, Jonkers J. (2012). The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer, 12, 587-98.
  4. Burg D, Filippov DV, Hermanns R, et al (2002). Peptidomimetic glutathione analogues as novel gamma GT stable GST inhibitors. Bioorg Med Chem, 10, 195-205.
  5. Gillet JP, Gottesman M. (2010). Mechanisms of multidrug resistance in cancer. Methods Mol Biol, 596, 47-76.
  6. Illuzzi JL, Wilson DM 3rd (2012). Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr Med Chem, 19, 3922-36.
  7. Jemal A, Bray F, Center MM, Ferlay JE (2011). Ward and D. Forman: Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  8. Larsen AK, Escargueil AE, Skladanowski A (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther, 85, 217-29.
  9. L i M, Wang ZJ, Li WT, Dong ZM (2006). Establishment of a cisplatininduced human esophageal carcinoma drugresistant cell line and its biological characteristics. WCJD, 14, 3257-61.
  10. L i M, Wang ZJ, Fu Q, Zhao GQ, Dong ZM (2007). Establishment of a cisplatin-induced human esophageal carcinoma drug resistant cell line and screening of drug resistance-related genes. Chin J Health Lab Technol, 17, 18-20.
  11. Li M, Zang WQ, Fu Q, Li WT, Dong ZM (2007). Correlation between overexpression ofDNA polymerase beta gene and drug-resistance of human esophageal carcinoma cells. J Fourth Mil Med Univ, 28, 1065-8.
  12. Liang XJ, Chen C, Zhao Y, Wang PC (2010). Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol, 596, 467-88.
  13. Li GC, Yang JM, Nie MM, et al (2005). Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma. Chin Med J, 118, 179-85.
  14. Liang XJ, Chen C, Zhao Y, Wang PC (2010). Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol, 596, 467-88.
  15. Li H, Zhou S, Li T (2012). Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrugresistant HCC cell line HEPG2/ADM by RNA interference. Hepatogastroenterology, 59, 2238-42.
  16. Maddalena F, Laudiero G, Piscazzi A, et al (2011). Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca (2+) homeostasis. Cancer Res, 71, 7659-69.
  17. Moroney J, Fu S, Moulder S,et al (2012). Phase I study of the antiangiogenic antibody bevacizumab and the mtor/hypoxiainducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res, 18, 5796-805.
  18. Rolland D, Raharijaona M, Barbarat A, Houlgatte R, Thieblemont C (2010). Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer Res, 30, 3951-7.
  19. Rygaard J, Povlsen CO (1969). Heterotransplantation of a humanmalignant tumour to "Nude" mice. Acta Pathol MicrobiolScand, 77, 758-60.
  20. Shen LZ, Hua YB, Yu XM, et al (2005). Tamoxifen can reversemultidrug resistance of colorectal carcinoma in vitro. WorldJ Gastroenterol, 11, 1060-4.
  21. Tang K, Lin Y, Li LM (2013). The role of phenethylisothiocyanate on bladder cancer ADM resistance reversaland its molecular mechanism. Anat Rec, 296, 899-906.
  22. Wang AL, Few KD (1985). Increased glutathione-S-transferaseactivity in a cell line with acquired resistance to nitrogenmustards. Cancer Treat Rep, 69, 677-82.
  23. Yin Q, Shen J, Chen L, et al (2012). Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly ($\beta$-amino esters). Biomaterials, 33, 6495-506.
  24. Yu DS, Hsieh DS, Chang SY (2006). Increasing expression ofGST-pi MIF, and ID1 genes in chemoresistant prostate cancercells. Arch Androl, 52, 275-81.
  25. Zhao LJ, Xu H, Qu JW, et al (2012). Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha $(PKC-\alpha)$ with small interference RNA (siRNA) agents. Asian Pac J Cancer Prev, 13, 3631-42.